Routine board appointment with no immediate trading catalyst. Monitor for any future strategic moves given Mr. Pauls' rare disease and M&A background, but no actionable signal from this filing alone.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 30 $152.82entry
- T+1 · 5mo ago −9.53%α −9.39% · $138.26
- T+5 · 4mo ago −8.19%α −8.79% · $140.31
- T+20 · 4mo ago −7.23%α −6.20% · $141.77
- T+60 · 8w ago −2.13%α −5.70% · $149.56
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Palvella Therapeutics appointed Matthew Pauls as a Class I director, expanding the board from seven to eight members. Mr. Pauls is the CEO of Savara, Inc. and brings rare disease and commercialization experience, including a prior board role at Soleno Therapeutics through its $2.9B acquisition. This is a routine board appointment with no material financial impact.
Key Facts
- Board expanded from 7 to 8 members on June 29, 2026
- Matthew Pauls appointed as Class I director, term expiring at 2027 Annual Meeting
- Mr. Pauls is CEO of Savara, Inc. (NASDAQ: SVRA)
- Granted option to purchase 6,000 shares vesting monthly over 36 months
- No related party transactions or family relationships with existing directors/officers
- Board determined Mr. Pauls is independent under Nasdaq rules
Financial Impact
Standard non-employee director compensation, option for 6,000 shares with 36-month vesting; annual retainer per policy. Immaterial relative to $2.1B market cap.
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-079087 |
| Document: 0001104659-26-079087-index-headers.html | 0001104659-26-079087 |
| Document: 0001104659-26-079087-index.html | 0001104659-26-079087 |
| Document: 0001104659-26-079087.txt | 0001104659-26-079087 |
Track record
36 reports on PVLA
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
- Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
- Nov 5, 202611d ago Press Release Neutral 6/10 No price data
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers